Drug Trial Radar · NCT06016088
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Apr 1, 2024
Primary completion
Apr 15, 2026
Study completion Jun 22, 2026
Sponsor
- Lead sponsor
- Respirion Pharmaceuticals Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
Conditions
- Cystic Fibrosis Lung
- Respiratory Infections, Recurrent, Chronic
- Pseudomonas Aeruginosa
Interventions
RSP-1502Drug
RSP-1502 is a sterile, preservative free solution to be administered by inhalation via a nebulizer. Each dose of RSP-1502 contains the active components tobramycin (300 mg) and CaEDTA in a 5 mL solution.
Tobramycin inhalation solutionDrug
Tobramycin inhalation solution is 300 mg tobramycin in 5 mL solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse eventsTime frame: Day 1 through Day 28
- Treatment-emergent serious adverse eventsTime frame: Day 1 through Day 28
- Changes in post-dose spirometryTime frame: Day 1, Day 2, and Day 14
- Pulmonary exacerbationsTime frame: Day 1 through Day 28
- Changes in post-dose electrocardiogram resultsTime frame: Day 1, Day 2, and Day 14
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Tucson Cystic Fibrosis Center
Tucson, Arizona
Center for Cystic Fibrosis at Keck Medical Center of USC
Los Angeles, California
Stanford University Medical Center
Palo Alto, California
Augusta University
Augusta, Georgia
The Cystic Fibrosis Institute
Northfield, Illinois
Tulane University
New Orleans, Louisiana
The Minnesota Cystic Fibrosis Center
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Columbia University Cystic Fibrosis Program
New York, New York
Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical Center
Cleveland, Ohio
Nationwide Children's Hospital
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Dell Children's Medical Center of Central Texas
Austin, Texas
Royal Prince Albert Hospital
Camperdown, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Queensland Children's Hospital
Brisbane, Queensland, Australia
The Prince Charles Hospital
Brisbane, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
The Royal Children's Hospital
Parkville, Victoria, Australia
Lung Institute of Western Australia
Nedlands, Western Australia, Australia
The Kids Research Institute Australia, Perth Children's Hospital
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.